{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-035924","form_type":"8-K","ticker":null,"cik":"0001463361","company_name":"Unity Biotechnology, Inc.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.701204+00:00","generated_at":"2026-05-25T01:08:06.689392+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"UNITY appoints Bausch + Lomb R&D chief Yehia Hashad to board; advances UBX1325","bullets":["Dr. Yehia Hashad, EVP R&D and CMO at Bausch + Lomb, joins board effective March 8, 2025.","Hashad also appointed to Science Committee; receives 20,000-share option grant (3-yr vest) + $45k annual cash retainer.","CEO cites Hashad's expertise as UNITY prepares for Phase 2b ASPIRE 24-week data readout for UBX1325 in DME.","Hashad brings 25+ years in ophthalmology and retinal drug development, including leadership at Allergan and Novartis.","Board chairman notes Hashad's strategic perspective will help advance UBX1325 and pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-035924","json":"https://secwatch.observer/filing/0000950170-25-035924.json","markdown":"https://secwatch.observer/filing/0000950170-25-035924.md","text":"https://secwatch.observer/filing/0000950170-25-035924.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1463361/000095017025035924/0000950170-25-035924-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1463361/000095017025035924/ubx-20250308.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T01:08:06.689392+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"991074b704","claim":"Yehia Hashad was appointed as Director at Unity Biotechnology, Inc..","evidence_excerpt":"On March 8, 2025, the Board of Directors (the “Board”) of UNITY Biotechnology, Inc. (“Unity” or the “Company”) appointed Dr. Yehia Hashad, M.D., current executive vice president of research & development and chief medical officer at Bausch + Lomb, to the Board and as a member of the Science Committee, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1463361/000095017025035924/0000950170-25-035924-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}